These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 25389307)

  • 1. Global origin and transmission of hepatitis C virus nonstructural protein 3 Q80K polymorphism.
    McCloskey RM; Liang RH; Joy JB; Krajden M; Montaner JS; Harrigan PR; Poon AF
    J Infect Dis; 2015 Apr; 211(8):1288-95. PubMed ID: 25389307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HCV genotype 1-6 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escape.
    Pham LV; Jensen SB; Fahnøe U; Pedersen MS; Tang Q; Ghanem L; Ramirez S; Humes D; Serre SBN; Schønning K; Bukh J; Gottwein JM
    J Hepatol; 2019 Mar; 70(3):388-397. PubMed ID: 30395912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region.
    Sarrazin C; Lathouwers E; Peeters M; Daems B; Buelens A; Witek J; Wyckmans Y; Fevery B; Verbinnen T; Ghys A; Schlag M; Baldini A; De Meyer S; Lenz O
    Antiviral Res; 2015 Apr; 116():10-6. PubMed ID: 25614456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphisms associated with resistance to protease inhibitors in naïve patients infected with hepatitis C virus genotype 1 in Argentina: Low prevalence of Q80K.
    Martínez AP; Culasso ACA; Pérez PS; Romano V; Campos RH; Ridruejo E; García G; Di Lello FA
    Virus Res; 2017 Aug; 240():140-146. PubMed ID: 28837817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vitro Activity of Simeprevir against Hepatitis C Virus Genotype 1 Clinical Isolates and Its Correlation with NS3 Sequence and Site-Directed Mutants.
    Verbinnen T; Fevery B; Vijgen L; Jacobs T; De Meyer S; Lenz O
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7548-57. PubMed ID: 26392483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The hepatitis C virus nonstructural protein 3 Q80K polymorphism is frequently detected and transmitted among HIV-infected MSM in the Netherlands.
    Newsum AM; Ho CK; Lieveld FI; van de Laar TJ; Koekkoek SM; Rebers SP; van der Meer JT; Wensing AM; Boland GJ; Arends JE; van Erpecum KJ; Prins M; Molenkamp R; Schinkel J
    AIDS; 2017 Jan; 31(1):105-112. PubMed ID: 27898592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patients eligible for treatment with simeprevir in a French center.
    Morel V; Duverlie G; Brochot E
    J Clin Virol; 2014 Sep; 61(1):149-51. PubMed ID: 25027573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance mutations are rare among protease inhibitor treatment-naive hepatitis C genotype-1 patients with or without HIV coinfection.
    Lisboa-Neto G; Noble CF; Pinho JR; Malta FM; Gomes-Gouvêa MS; Alvarado-Mora MV; da Silva MH; Leite AG; Piccoli LZ; Rodrigues FK; Carrilho FJ; Mendes-Correa MC
    Antivir Ther; 2015; 20(3):281-7. PubMed ID: 25279715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predominance of hepatitis C virus Q80K among NS3 baseline-resistance-associated amino acid variants in direct-antiviral-agent-naïve patients with chronic hepatitis: single-centre experience.
    Ruggiero T; Proietti A; Boglione L; Milia MG; Allice T; Burdino E; Orofino G; Bonora S; Di Perri G; Ghisetti V
    Arch Virol; 2015 Nov; 160(11):2881-5. PubMed ID: 26249823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular characterization of hepatitis C virus for determination of subtypes and detection of resistance mutations to protease inhibitors in a group of intravenous drug users co-infected with HIV.
    Silva T; Cortes Martins H; Coutinho R; Leitão E; Silva R; Pádua E
    J Med Virol; 2015 Sep; 87(9):1549-57. PubMed ID: 25940586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virologic response and characterisation of HCV genotype 2-6 in patients receiving TMC435 monotherapy (study TMC435-C202).
    Lenz O; Vijgen L; Berke JM; Cummings MD; Fevery B; Peeters M; De Smedt G; Moreno C; Picchio G
    J Hepatol; 2013 Mar; 58(3):445-51. PubMed ID: 23142061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a.
    Palanisamy N; Danielsson A; Kokkula C; Yin H; Bondeson K; Wesslén L; Duberg AS; Lennerstrand J
    Antiviral Res; 2013 Jul; 99(1):12-7. PubMed ID: 23648709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epistatic interactions promote persistence of NS3-Q80K in HCV infection by compensating for protein folding instability.
    Dultz G; Srikakulam SK; Konetschnik M; Shimakami T; Doncheva NT; Dietz J; Sarrazin C; Biondi RM; Zeuzem S; Tampé R; Kalinina OV; Welsch C
    J Biol Chem; 2021 Sep; 297(3):101031. PubMed ID: 34339738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and Validation of Two Screening Assays for the Hepatitis C Virus NS3 Q80K Polymorphism Associated with Reduced Response to Combination Treatment Regimens Containing Simeprevir.
    Chui CK; Dong WW; Joy JB; Poon AF; Dong WY; Mo T; Woods CK; Beatty C; Hew H; Harrigan PR; Brumme CJ
    J Clin Microbiol; 2015 Sep; 53(9):2942-50. PubMed ID: 26135875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5.
    Vallet S; Viron F; Henquell C; Le Guillou-Guillemette H; Lagathu G; Abravanel F; Trimoulet P; Soussan P; Schvoerer E; Rosenberg A; Gouriou S; Colson P; Izopet J; Payan C;
    Antivir Ther; 2011; 16(7):1093-102. PubMed ID: 22024525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Worldwide distribution of the NS3 gene 80K polymorphism among circulating hepatitis C genotype 1 viruses: implication for simeprevir usage.
    Vidal LL; Santos AF; Soares MA
    J Antimicrob Chemother; 2015 Jul; 70(7):2024-7. PubMed ID: 25835991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of naturally occurring protease inhibitor resistance-associated variants in hemodialysis and renal transplant patients with hepatitis C virus infection.
    Tavares RCF; Feldner ACCA; Pinho JRR; Uehara SNO; Emori CT; Carvalho-Filho RJ; Silva ISS; Santana RAF; de Castro VFD; Castoli GTF; Cristovão CU; Ferraz MLCG
    Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):754-758. PubMed ID: 28234637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of naturally occurring amino acid substitutions associated with resistance to hepatitis C virus NS3/NS4A protease inhibitors in São Paulo state.
    Moreira RC; de Torres Santos AP; Lisboa-Neto G; Mendes-Corrêa MCJ; Lemos MF; Malta FM; Santana RAF; Dastoli GTF; de Castro VFD; Pinho JRR
    Arch Virol; 2018 Oct; 163(10):2757-2764. PubMed ID: 29961118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Determination of the naturally occurring Q80K mutation in the HCV NS3 protease gene].
    Kutová R; Plíšková L; Štěpánová V; Plíšek S; Machač J
    Klin Mikrobiol Infekc Lek; 2015 Dec; 21(4):126-9. PubMed ID: 26886497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of the NS3 Q80K polymorphism by Sanger and deep sequencing in hepatitis C virus genotype 1a strains in the UK.
    Beloukas A; King S; Childs K; Papadimitropoulos A; Hopkins M; Atkins M; Agarwal K; Nelson M; Geretti AM
    Clin Microbiol Infect; 2015 Nov; 21(11):1033-9. PubMed ID: 26232533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.